News & Events about Neurocrine Biosciences Inc.
- Voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial milestones, tiered royalties on net sales, program funding, and an option to elect 50/50 cost- and profit-...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX Get Rating) Director Stephen A. Sherwin sold 30,000 shares of the firms stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $118.86, for a total value of $3,565,800.00. Following the completion of the transaction, the ...
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX Get Rating) have earned an average rating of Moderate Buy from the twenty analysts that are presently covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a hold recommendation, ...
Symbols mentioned in this story: MDYG, STLD, NBIX, TTC
Exchange traded funds (ETFs) trade just like stocks, but instead of shares investors are actually buying and selling units. These units can be traded back and forth just like stocks, ...